Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BRII-198 in healthy volunteers
NCT04479644Phase 1Completed
- Sponsor
- Brii Biosciences
- Start
- Jul 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of romlusevimab in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Brii Biosciences. Primary endpoints: Incidence of adverse events (AEs) by CTCAE v5.0 at 24 weeks, Proportion of subjects with SAEs at 24 weeks and 2 more. Started Jul 2020; status: completed.
02
Drugs
romlusevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04479644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479644.